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ABSTRACT
The multidrug resistant Escherichia coli strains causes multiple clinical infections and has become a rising problem
globally. The metallo-β-lactamases encoding genes are very severe in gram-negative bacteria especially E. coli. This
study was aimed to evaluate the prevalence of MBLs among the clinical isolates of E. coli. A total of 65 E. coli isolates
were collected from various clinical samples of Malaysian patients with bacterial infections. The conventional
microbiological test was performed for isolation and identification of E. coli producing MBLs strains in this vicinity.
Multidrug Resistance (MDR) of E. coli isolates were assessed using disk diffusion test. Phenotypic methods, as well as
genotypic- PCR methods, were performed to detect the presence of metallo-β-lactamase resistance genes (blaIMP,
blaVIM) in imipenem resistant strains. Out of 65 E. coli isolates, 42 isolates (57.3%) were MDR. The isolates from
urine (19) produced significantly more MDR (10) isolates than other sources. Additionally, 19 (29.2%) imipenem-
resistant E. coli isolates contained 10 MBLs gene, 7(36.8%) isolates contained blaIMP and 3(15.7%) isolates contained
blaVIM genes. This study revealed the significant occurrence of MBL producing E. coli isolates in clinical specimens and
its association with health risk factors indicating an alarming situation in Malaysia. It demands an appropriate concern
to avoid failure of treatments and infection control management.
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INTRODUCTION
Treatment of bacterial infections has become
complicated due to the emergence of multi-drug
resistant strains of Escherichia coli. E. coli showed the
highest antibiotic resistance trends among the
different types of bacteria in Malaysia between 2013
and 2017 (Fazlul et al., 2018). Metallo-beta-
lactamases (MBLs) are beta-lactamase enzymes
produced by pathogenic bacteria and gradually
found in Gram-negative organisms, mostly in E. coli
species. Clinical infections with MBL-producing
isolates are associated with higher morbidity and
mortality (Deshmukh et al., 2011). However,
carbapenem resistance due to Metallo-beta-
lactamases (MBLs) production has been gradually
reported among clinical isolates of E. coli (Bora et
al., 2014; Nepal et al., 2017). Among
Enterobacteriaceae species, the blaIMP and blaVIM
genes have been identified throughout the world.
The prevalence rate of carbapenem resistance E. coli
is higher by acquiring MBL including imipenem (IPM)
and Verona integron-encoded Metallo-β-lactamase
(VIM) around the world. Metallo-β -lactamases
(MBLs) which hydrolyze the carbapenems (imipenem,
meropenem, and ertapenem) and render them
ineffective for treatment (Meletis, 2016; Morrill et al.,
2015). In addition, MBLs are not susceptible to
therapeutic β- lactamase inhibitors like sulbactam,
tazobactam, or clavulanic acid (Drawz et al., 2014;
Everaert and Coenye, 2016; Watkins et al., 2013).
The emergence and uncontrolled spread of
carbapenems in Gram-negative bacteria are under
threat (Chika et al., 2014) but normally
carbapenems are used for the treatment of infections
caused by β-lactam resistant bacteria including
extended-spectrum enzymes producers (Bashir et al.,
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2011). The unusual reduced susceptibility of bacterial
pathogens to MBLs as reported as increasing
concern matter  (Chakraborty et al., 2010).
Carbapenem-resistant Enterobacteriaceae can cause
several severe infections, especially in healthcare
settings over the last decade. The rising
carbapenems resistant organisms has become a risk
factor to existing antibiotics used for handling
nosocomial infections (e.g. bacteremia, septicemia,
and pneumonia in children). The recurrence rate of
five different types of MBLs (IMP, VIM, SPM, GIM and
SIM) are increasing rapidly while IMP and VIM types
existence in-universe (Gupta, 2008). In vitro
chelating agents (EDTA and dipicolinic acid) inhibit
MBLs enzyme, can be detected phenotypically
in pathogenic bacteria (Chika et al., 2014). MBLs
gene expression can be either plasmid-mediated or
chromosomal (El Salabi et al., 2013; Smet et al.,
2010). The standard methods are modified Hodge
test (MHT), double-disc synergy test (DDST),
combined disc diffusion test using imipenem and
EDTA, and MBL E-test (Sachdeva et al., 2017).
Among the phenotypic methods, DDST methods are
less sensitive compared to CDT for detecting MBL
genes (Jorth et al., 2017; Mehta and Prabhu, 2016;
Nermine et al., 2015) but earlier MHT were much
sensitive then DDST (Shivaprasad et al., 2014). MBLs
production can be assessed by molecular methods
and phenotypic methods. Among the molecular
techniques, polymerase chain reaction (PCR), DNA
probes, cloning and sequencing are highly accurate
to identify MBL-positive genes (Sachdeva et al.,
2017). Metallo beta-lactamase producing gram-
negative bacteria are frequently shown resistance to
variance classes of drugs associated with multi-drug
resistant bacteria (Meletis, 2016). Hence, the
consistent detection of the MBL-producing genes is
vital for appropriate treatment for nosocomially
infected patients and quality management of multi-
drug resistant bacteria (Doosti et al., 2013). The
improvement and innovation of antimicrobials
agents with novel innovation are in need to manage
infectious diseases effectively (Fazlul MKK, 2018).The
objective of this study was to evaluate the prevalence
rate of MBLs producing E. coli and its increasing
trends in Malaysia. The clinical observation of this
study will be helpful for rapid detection of resistance
mechanism due to seveal metallo-β-lactamases-
encoding genes to prevent the spreading of these
microorganisms.
Materials And Methods
Sixty-five strains of bacterial samples were collected
and identified as Escherichia coli using 16SrRNA with
the universal primers 27f (5’-
AGAGTTTGATCCTGGCTCAG-3’) and 1492r (5’-
GGTTACCTTGTTACGACTT-3’) (Tissera and Lee,
2013). Only the patients having bacteriological
evidence of clinical features were included in this
study. The sources of studied isolates are as follows:
urine, 19 (29%); wounds, 9(14%); respiratory tract,
12(18%); stool, 17(26%); sputum, 3(5%) and blood,
5(8%).
Antimicrobial susceptibility Test
Antibiotic susceptibility was performed for all 65
clinical isolates of Escherichia coli by Kirby Bauer disc
diffusion method in accordance with CLSI-2017
guidelines incorporating standard strain of
Escherichia coli. Different types of antibiotics
(tazobactam 10/ piperacillin 75- TZP, ceftazidime-
CAZ, ciprofloxacin-CIP, meropenem-MEM,
imipenem-IPM, cefepime-FEP, cefotaxime-CTX,
aztreonam-ATM, amoxicillin-clavulanic acid-AMC,
cefoperazone -CPZ) were used for susceptibility
patterns of E. coli.  In the screening of MBL
producing E. coli strains, EDTA powder was used.
Carbapenem-resistant were considered when the
zone of inhibition was around imipenem ≤ 13 mm,
intermediate 14-15 mm and sensitive ≥ 16 mm
(CLSI, 2017). Imipenem-resistant isolates were
further screened for of metallo-β-lactamases-
encoding genes.
Modified Hodge test
The Modified Hodge Test (MHT) was performed to
detect carbapenemase among the Escherichia coli
strains in this study. A lawn culture of 1:10 dilution of
0.5 McFarland's standard Escherichia coli ATCC
25922 was cultured on a Muller-Hinton (MH) agar
and allowed to dry 3-5 minutes. A 10 μg imipenem
disc was placed in the center of the plate. Imipenem-
resistant E. coli (test isolates) in a straight line,
streaked from the edge of the disk to the edge of the
plate. Four E. coli strains were tested on the same
plate with one drug. The carbapenem disc of
imipenem (10 µg) or meropenem (10 µg) was placed
at the middle of the plate. E. coli growth was spotted
in imipenem disk (within the inhibition zone) by
indicating a distorted zone.
The double-disc synergy test
Double disk synergy test was assessed by the CLSI
guidelines for the disk diffusion method (CLSI, 2017).
An opacity of 0.5 McFarland of test organism was
streaked on the MHA using a sterile cotton swab to
get a lawn culture. Imipenem (10 ug) disc was
placed in 20 mm center to center from a blank disc
contained 10 µl of 0.5 M EDTA (750 ug) or EDTA
disc (750 ug). The cultured plate was kept in
incubator for 16 to 18 hours at 37°C (Fazlul MKK,
2018; Nazmul et al., 2017; Suryadevara et al.,
2017). The occurrence of a synergistic inhibitory
zone was viewed indicating MBL positive isolates.
Combined disc diffusion method
A lawn culture of test isolates (0.5 McFarland opacity
standard) was streaked on MH agar and left it to dry
for 3-5min. Two 10 μg imipenem discs were kept on
inoculated plates at distance of 25mm. Ten μl of 0.5
M EDTA solution was added to one of the imipenem
discs. The zone of inhibition of imipenem + EDTA
discs compared to imipenem alone is >7 mm after
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overnight incubation. The test outcome was
considered as positive (Kali et al., 2013; Suryadevara
et al., 2017) and the procedure was repeated twice
to ensure the results.
E-test
An E-test MBL strip contains imipenem (4–256 μg/ml)
and imipenem (1–64 μg/ml) in combination with a
fixed concentration of EDTA. A 0.5 McFarland of test
isolates was cultured on on MH agar. E-test strip was
inoculated for 24 hours on the surface of the agar,
and the plates were observed for imipenem and
imipenem–EDTA minimum inhibitory concentration
(MIC) values more than eight was considered as
positive
DNA preparation and PCR amplification
DNA template preparation was performed to detect
the MBLs resistant genes of E. coli isolates and
suspended in 300 μL of water (sterile distilled) and
boiled for 10 min. Then centrifuge at 12000 × g for
10 min. Formation of supernatant was used as a
template DNA for PCR amplification of blaIMP and
blaVIM genes. PCR amplification was solution
containing 200 µM concentrations of dNTP, of each
primer (10 pM), 1.5 mM MgCl2, Taq polymerase
(0.5 U) and 50 ng DNA templates of total 25 µL final
volume. The amplicon sizes and sequences of
primers are shown in Table 1. The blaIMP and
blaVIM genes were amplified under a specific
condition (Table 2). Escherichia coli ATCC 25922
was used as negative controls. The PCR products
were visualised by agarose gel electrophoresis
stained with ethidium bromide (5 μg/100 mL).
Table 1: Primers for PCR amplification
Gene
target (s) Primer sequence
Expected
amplicon
size (bp)
References
blaIMP 5'-CTACCGCAGCAGAGTCTTTG-3' 587 (Shibata et al., 2003)5'-AACCAGTTTTGCCTTACCAT -3'
blaVIM 5'-CCGATGGTGTTTGGTCGCAT -3' 261 (Athanassios Tsakris et al., 2000)5'-GAATGCGCAGCACCAGGA -3'
Table 2: PCR programs for amplification
Primers were designed to detect the presence of the
metallo-β-lactamase genes, blaVIM (261bp) (A.
Tsakris et al., 2000) and blaIMP (587bp) (Shibata et
al., 2003) (Table 1). Thermocycling conditions for
PCR amplification are shown in table 2.
Results and Discussion
During this study, antibiotic resistance rate of E. coli
isolates (65) was determined. All the E. coli isolates
were collected from both male and female patients
according to age.  The highest 40% of the patients
were at the age of 31-45 years old whereas the least
(1%) above 60 years (Table 3).
Table 3: Sex-dependent E. coli isolates
The range of Age
Groups in Years
Gender Total no (%)Male Female
1-15 years 3 2 8
16-30 years 7 13 31
31-45 17 9 40
46-60 8 5 20
Above 60 1 0 1
All the clinical strains of E. coli (65) were identified
and confirmed by conventional bacteriological tests
(16SrRNA) using the universal primers with an
expected amplicon of 1500bp (Tissera and Lee,
2013). All E. coli isolates (65) were collected from
different clinical samples, urine (29%) followed by
stools (26%), respiratory (18%), wounds (14%), blood
(8%) and sputum (5%) respectively.Characterisation
of Escherichia coli (65) was assessed based on the
standard guidelines where E. coli isolates produce
pinkish colonies on MacConkey agar, ferments
lactose and metallic sheen colonies on Eosin
methylene blue agar (Table 4).
Target
gene
First
denaturation
Extension Annealing Denaturation Final
extension
References
blaVIM 95°C 5 min 72°C 7 min 72°C 1 min 58°C 1 min 95°C1 min (Yousefi et
al., 2010)blaIMP 95°C 5 min 72°C10 min 72°C 1 min 54°C 40 s 95°C1 min
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Table 4: Isolation and characterisation of Escherichia coli
%: Percentage, +Ve: Positive, -Ve: Negative, EBM: Eosin methylene blue agar, MAC: MacConkey agar
Ten different types of commonly prescribed
antibiotics have been used in this study to evaluate
and to compare the antibiotic susceptibility rate
between the isolates from male and female patients
but exposed no significant variance (P >.05). Sixty-
five isolates of Escherichia coli clinical isolates were
highly resistant to cefalexin, cefepime, aztreonam,
and cefotaxime with a resistance rate of 89.2%,
86.1%, 83.6%, and 78.4%, respectively. The least
resistant 29.2% to imipenem was observed (Figure
2).
Table 5: Multidrug-resistant (MDR) among the E. coli (65) isolates
No and Types of
Antibiotics Types of antibiotics No (%) of MDR E. coli isolates
3 classes of antibiotics CTX, TZP, IMP 12 (19%)
4 classes of antibiotics ATM, MEM, CIP 15 (23%)
5 classes of antibiotics MEM, AMC, FEP, AMP, CEX 10 (15%)
6 classes of antibiotics AMC, CTX, ATM, IMP, CIP, CEX 3(5%)
10 classes of antibiotics TZP, CAZ, CIP, MEM, IMP, FEP, CTX,ATM, AMC, CEX 2(3%)
42(65%)
Figure 1: Antibiotic susceptibility
Tazobactam 10/ Piperacillin 75- TZP, Ceftazidime-
CAZ, Ciprofloxacin-CIP, Meropenem-MEM,
Imipenem-IPM, Cefepime-FEP, Cefotaxime -CTX,
Aztreonam – ATM, Amoxicillin-clavulanic acid –
AMC, Cefalexin -CEX. The prevalence rate of
antibiotic resistance among 65 E. coli isolates 42
(65%) were found to be resistant to three to six
antibiotics and regarded as multi-drug resistant
isolates (MDR) (Table 5). Also, 3% (2/65) isolates
were resistant to all used antibiotics in this study.
Among 42 MDR clinical samples, stool produced the
highest resistant organisms 30.9%, followed by
respiratory 21.4% and the least was produced by
sputum 4.7% (Figure 2).
Organism Indole test Methylred test
Gram
staining Colonies features No of Isolates
Escherichia coli +Ve +Ve -Ve
Metallic sheen colonies on
EMB and Pinkish colonies on
MAC
65
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Figure 2: Frequency of MDR and MBL producers among the clinical specimens
In this present study, disk diffusion test confirmed 19
(29.2%) isolates resistant to IPM. Among the 19 IPM
resistant strains, 12 (63.15%) strains were MIC≥4
µg/ml for IPM by the E-test (bioMérieux, Marcy
l’Etoile, France). Phenotypic assays such as CDT,
DDST, and MHT were found to be sensitive to
determine MBLs producing gene in this study. Among
the 19 isolates of imipenem resistant E. coli, each of
the phenotypic assays differs while the most specific
by DDST 52.6%, followed by CDT (47.4%) and MHT
was the least specific (36.8%) (Table 6). A zone of
>4 mm diameter observed around the imipenem-
EDTA disc compared to imipenem disc alone (Figure
3).  Studies have shown that phenotypic methods
have specificities as similar to PCR and sensitive
enough to detect MBL producing isolates (Yalda
Khosravi et al., 2012).
Figure 3: Positive combined disc test for detection of MBL producer by use of EDTA.
Table 6: Frequency of MBL-producing E. coli detected by the inhibition-based assay
Imipenem resistance 29.2% E. coli strains were
screened to detect MBLs gene. MBLs genes (blaIMP,
blaVIM) were detected in 10 (52.6%) isolates by PCR
genotypic confirmative test. Among these MBLs (10)
gene, urine produced the highest 4 (40%) followed
by respiratory and wounds 2 (20%) (Figure 1). These
Imipenem-
resistant
Escherichia
coli isolates
MHT (Modified Hodge
test)
Double-disc synergy test
Ceftazidime +
(Ceftazidime + EDTA) E -
strip method
Combined disc test
Imepenem + (Imepenem +
EDTA) Combined disc
diffusion
Positive Negative Positive Negative Positive Negative
19 7(36.8%) 12(63.2%) 10 (52.6%) 9 (47.4%) 9(47.4%) 10 (52.6%)
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10 strains were then analyzed by PCR and blaIMP
gene was present in 7 (12.5%) isolates while 3 (5.4%)
isolates carried the blaVIM gene (Figure 4).
Figure 4: the frequency of MBL genes detected in the 10 Escherichia coli
Discussion
Enterobacteriaceae produces Metallo beta-lactamase
(MBL), is one of the mechanisms associated with
severe bacterial infections. Antibacterial resistance
micro-organisms limit and complicate treatment
which is difficult to overcome due to multidrug
resistant properties. The outcome of this study
showed a high prevalence of Escherichia coli from
several sources of clinical samples associated with
multiple resistance genes.In a previous investigation,
sex-dependent antibiotic resistance was established
(Ben-Ami et al., 2009) while in a recent study, age
was not a substantial issue in defining the antibiotic
resistance but gender plays a vital role in the
sensitivity (Lee et al., 2016). This study revealed that
no antibiotic resistance significant variance in
between the males and females (P >.05) which is
also in agreement with a previous study by Ghadiri
(Ghadiri et al., 2014). In this present study, the
maximum number (19 isolates) of urine carried 40%
of MBLs producing gene which agreed with other
study defined previously (Anago et al., 2015).
Furthermore, a study in Indonesia in which sputum
was the highest carriage of these genes (Karuniawati
et al., 2013) and most (47.7%) resistant gene was
isolated from pus swabs (Okoche et al., 2015). More
than 80% of the urinary tract infections (UTI) while
female febrile UTIs 86.3% and male febrile UTIs
78.5% are due to E. coli (Lee et al., 2016).
Misappropriation of antibiotic is liable for the higher
incidence of antibiotic resistance among bacteria
(Neupane et al., 2016). In this study, 65% E. coli
isolates were multidrug resistant which are in
agreement with a number of studies, 95.52% (Yadav
et al., 2015), 73.68% (Thakur et al., 2013), 57.3%
(Nairoukh et al., 2018) and 40.7% isolates in
Tehran (Ghadiri et al., 2014).  In this study, E. coli
isolates exhibited variable rates of susceptibility and
resistance to 10 different types of antibiotics. The
highest percentage of resistant to CEX (89.1%) and
cefepime (86.1%) agrees to 83.16% and 100%
resistance respectively in Nepal (Jena et al., 2017).
The E. coli resistant rate of cefotaxime (84.4%) and
ceftazidime (81.3%) (Chika et al., 2016) are
consistent with the results found in this study. In
contrast, a higher resistant to ceftazidime (100%) and
cefotaxime (100%) was observed (Jena et al., 2017).
However, among the carbapenem group of
antibiotics, imipenem showed the least resistant
(29.2%) correspond with data presented
previously 17% (Jena et al., 2017), 7.37% (Yadav et
al., 2015), 22% isolates of E. coli (Adwan et al.,
2014). In contrast, the higher resistant rate (82%)
was observed in 2015 (Rezai et al., 2015) while
100% isolates were imipenem resistant (Liang et al.,
2017) compared to this present study. Bacterial
resistance due to metallo-β-lactamase (MBL)
production is increasing (Nazmul et al., 2017). This
study demonstrates screening for MBL producing
imipenem resistant E. coli isolates (19) by three
different phenotypic approaches differs in MHT (7,
36.8%), CDT (9, 47.4%) and DDST (10, 52.6%) for
MBL positive strains. However, PCR results confirmed
the occurrence of MBL genes in imipenem resistant E.
coli 10/19 (52.6%) isolates same as by DDST
method. Moreover, 70.0% isolates were MBL
producers (Ghadiri et al., 2014) which are agreeing
to this study. This present study revealed a strong
association between MBLs gene presence and MDR
resistant E. coli (Figure 1). In addition, number of
study observed a lower rate of 18.98% (Bora et al.,
2014), 12.5% (Jena et al., 2017), 4.2% (Agbo and
Eze, 2015) and 28.6% strains (Chika et al., 2014)
were MBL producing E. coli. The prevalence rate of
MBLs 53% was observed in E. coli (Marie et al.,
2013) which is in agreement to this study and Mita
and his colleagues (Wadekar et al., 2013) has
reported a lower prevalence rate of MBLs (13.4%).
The variances between phenotypic and genotypic
determination of MBL producing Escherichia coli
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isolates have been reported in earlier studies
(Okoche et al., 2015).An increase acquisition of MBL
genes such as blaIMP and blaVIM (Mohanam and
Menon, 2017), (Y. Khosravi et al., 2010), (Salimi and
Eftekhar, 2014), (Liew et al., 2018) was observed
throughout the world. Among the MBL-encoding
genes, blaVIM are the most prevalent worldwide,
followed by blaIMP (Y. Khosravi et al., 2010; Salimi
and Eftekhar, 2014) but this study revealed the
prevalence of blaIMP is higher than blaVIM. The PCR
amplification products of MBLs producing genes
(blaIMP and blaVIM) was observed in this present
study. Among the imipenem-resistant Escherichia
coli, ten strains (52.6%) carried 1 or both MBL genes
as shown in single PCR experiments (Figure- 5).
Imipenem resistant gene blaIMP was observed in
7(70%) and blaVIM in 3 isolates (30%), of which 1
carried both genes. A recent study has revealed 8
imipenem resistant E. coli genotypically confirmed to
harbor blaIMP gene by the multiplex PCR and while
blaVIM was absent (Chika et al., 2016). In contrast,
some of the recent studies showed both blaIMP and
blaVIM genes were absent (Liang et al., 2017;
Nairoukh et al., 2018).
Conclusion
In conclusion, the prevalence rate of antibiotic
resistance, both blaIMP and blaVIM type MBL
producing E. coli strains is in alarming condition
compared to other parts of the world. The hospital
should highlight the clinically relevant strains for
MBLs producing microorganisms and management
of quality control infectious disease. The higher
prevalence rate of antibiotic-resistant and β-
lactamase producing E. coli are associated risk
factors demands epidemiological study, advance
attention and concern to stop spreading of MBLs
genes producing gram-negative bacteria in the
community.
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